Regulatory expansion is a positive catalyst but launches are over a year away. Monitor upcoming earnings for initial European revenue forecasts and country-level pricing negotiations.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $81.81entry
- T+1 · 7mo ago +4.61%α +4.95% · $85.58
- T+5 · 6mo ago +15.11%α +12.76% · $94.17
- T+20 · 6mo ago +7.41%α +2.12% · $87.87
- T+60 · 4mo ago +32.06%α +28.99% · $108.04
Price Chart
How similar events traded
Executive Summary
Rhythm Pharmaceuticals received European Commission approval for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity in adults and children aged 4+. This expands the addressable market by approximately 10,000 patients in Europe, building on the FDA approval in March 2026. Commercial launches are expected in 2027.
Key Facts
- EC authorized IMCIVREE for acquired hypothalamic obesity in all EU member states
- Pivotal Phase 3 TRANSCEND trial showed -19.8% placebo-adjusted BMI reduction (p<0.0001)
- Approximately 10,000 patients in Europe with acquired HO
- FDA approved same indication on March 19, 2026
- Commercial launches anticipated in 2027
Financial Impact
Expands TAM by ~10,000 European patients; no revenue guidance provided
Risk Factors
- Competition from other obesity treatments
- Reimbursement and access challenges in Europe
- Safety concerns including adrenal insufficiency and psychiatric events
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285813 |
Track record
26 reports on RYTM
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +31.83% at T+5 after the Nov 3, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers